Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single Center, Randomized, 4-way Crossover, Double Blinded, Placebo And Moxifloxacin Controlled Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects

Next Previous
X
Search
Trial Profile

A Phase 1, Single Center, Randomized, 4-way Crossover, Double Blinded, Placebo And Moxifloxacin Controlled Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glasdegib (Primary) ; Moxifloxacin
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Glioblastoma; Graft-versus-host disease; Haematological malignancies; Myelodysplastic syndromes; Myelofibrosis; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pfizer

    • Most Recent Events

    • 31 Oct 2017 Status changed from recruiting to completed.
    • 05 Jul 2017 Planned End Date changed from 23 Oct 2017 to 16 Oct 2017.
    • 05 Jul 2017 Planned primary completion date changed from 25 Sep 2017 to 23 Sep 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top